Therapies targeting integrins other than MAC1, including humanized anti-CD11a, anti-ICAM1 and anti-CD18, have been associated with increased incidence of infection in clinical trials, including increased fungal and bacterial infections, [40–43]. This evidence concerns the gene ITGB2 and bacterial infectious disease.